Haifa, Israel

Shira Toledano

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Rambam Med-Tech Ltd., Technion Research & Development Foundation Ltd. Active years: 2020.


 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2020

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Shira Toledano: Innovator in Eye Disease Treatment

Introduction

Shira Toledano is a notable inventor based in Haifa, Israel. She has made significant contributions to the field of medical research, particularly in the treatment of eye diseases. Her innovative work has led to the development of a patent that addresses critical health issues.

Latest Patents

Shira Toledano holds a patent for "Semaphorin 3C variants, compositions comprising said variants and methods of use thereof in treating eye diseases." This invention focuses on methods for treating eye diseases, such as age-related macular degeneration (AMD), by administering Semaphorin 3C or a variant with specific amino acid modifications. These modifications make the cleavage sites resistant to furin-like pro-protein convertase cleavage, enhancing the treatment's effectiveness.

Career Highlights

Throughout her career, Shira has worked with esteemed organizations, including the Technion Research & Development Foundation Limited and Rambam Med-tech Ltd. Her experience in these institutions has allowed her to advance her research and contribute to innovative solutions in healthcare.

Collaborations

Shira has collaborated with notable colleagues, including Ofra Kessler and Gera Neufeld. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise in the field of medical research.

Conclusion

Shira Toledano's contributions to the treatment of eye diseases through her patented innovations highlight her role as a leading inventor in the medical field. Her work continues to inspire advancements in healthcare and improve patient outcomes.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…